FY2025 Earnings Estimate for AVBP Issued By Lifesci Capital

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Research analysts at Lifesci Capital dropped their FY2025 earnings per share estimates for shares of ArriVent BioPharma in a research report issued on Monday, March 3rd. Lifesci Capital analyst S. Slutsky now anticipates that the company will post earnings per share of ($3.97) for the year, down from their prior estimate of ($3.80). The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. Lifesci Capital also issued estimates for ArriVent BioPharma’s FY2026 earnings at ($4.49) EPS.

Separately, HC Wainwright upped their price objective on shares of ArriVent BioPharma from $36.00 to $39.00 and gave the company a “buy” rating in a report on Wednesday, January 22nd.

ArriVent BioPharma Trading Up 2.4 %

Shares of ArriVent BioPharma stock opened at $22.47 on Thursday. The business’s 50 day moving average price is $26.40 and its 200 day moving average price is $27.16. ArriVent BioPharma has a one year low of $14.35 and a one year high of $36.37.

ArriVent BioPharma (NASDAQ:AVBP) last released its earnings results on Monday, March 3rd. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.18.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of AVBP. Charles Schwab Investment Management Inc. lifted its holdings in shares of ArriVent BioPharma by 153.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 202,368 shares of the company’s stock worth $4,756,000 after acquiring an additional 122,641 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in ArriVent BioPharma during the third quarter worth $240,000. FMR LLC boosted its position in shares of ArriVent BioPharma by 8.7% during the third quarter. FMR LLC now owns 2,119,695 shares of the company’s stock worth $49,813,000 after buying an additional 169,514 shares during the period. BNP Paribas Financial Markets grew its stake in shares of ArriVent BioPharma by 32.6% in the third quarter. BNP Paribas Financial Markets now owns 21,965 shares of the company’s stock valued at $516,000 after buying an additional 5,397 shares in the last quarter. Finally, MetLife Investment Management LLC raised its holdings in shares of ArriVent BioPharma by 168.9% in the 3rd quarter. MetLife Investment Management LLC now owns 16,350 shares of the company’s stock valued at $384,000 after buying an additional 10,269 shares during the period. Institutional investors and hedge funds own 9.48% of the company’s stock.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.